TD Cowen Boosts Quanterix (NASDAQ:QTRX) Price Target to $16.00

Quanterix (NASDAQ:QTRX) had its target price hoisted by TD Cowen from $13.50 to $16.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “hold” rating on the stock. TD Cowen’s price target points to a potential upside of 34.23% from the company’s previous close.

Separately, Scotiabank decreased their price objective on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a report on Monday, August 12th.

Quanterix Price Performance

QTRX stock opened at $11.92 on Wednesday. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70. The business has a fifty day moving average of $12.97 and a two-hundred day moving average of $14.01.

Insiders Place Their Bets

In related news, Director David R. Walt acquired 47,000 shares of the business’s stock in a transaction on Tuesday, August 20th. The shares were bought at an average price of $13.29 per share, with a total value of $624,630.00. Following the completion of the acquisition, the director now owns 1,487,342 shares in the company, valued at $19,766,775.18. This trade represents a 3.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 6.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On Quanterix

Large investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in shares of Quanterix in the third quarter valued at approximately $60,000. SG Americas Securities LLC purchased a new position in Quanterix during the 3rd quarter valued at about $139,000. Canada Pension Plan Investment Board acquired a new position in Quanterix in the 2nd quarter valued at about $140,000. Hsbc Holdings PLC raised its position in shares of Quanterix by 34.7% in the second quarter. Hsbc Holdings PLC now owns 12,738 shares of the company’s stock valued at $164,000 after buying an additional 3,279 shares during the last quarter. Finally, Intech Investment Management LLC purchased a new position in shares of Quanterix during the 3rd quarter worth $170,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.